NL
DE
Current HPV-DNA testing in population screening for cervical cancer might have had it best time. A new test originating from Radboudumc gives a decisive answer within four days.
Related news items
Aftermovie Investment Day 2022 and a new date for 2023!
13 December 2022Over 100 scientists, investors, and entrepreneurs came together to accelerate innovation in healthcare by creating new business opportunities and forging strong public-private partnerships.
read more
Successful matchmaking at Radboudumc Investment Day
7 October 2022On the 5th of October, over 100 scientists, investors and entrepreneurs came together at the second Radboudumc Investment Day, jointly hosted by Radboudumc, Oost NL and Briskr.
read more
Radboudumc Investment Day 2022
26 September 2022Get ready for Radboudumc Investment Day 2022: October 5 in Nijmegen!
read more
Innovation by Predica Diagnostics BV improves cervical cancer screening
26 July 2022A joint financing round from ION+2 and the Thematic Technology Transfer Medtech Fund (TTT Medtech) allows the further development of molecular diagnostic tests for different cancers by Predica Diagnostics (Nijmegen, NL).
read more
BIOTRIP vision for biotech incubator
9 November 2021 BIOTRIP, the biotech incubator, presents its vision. read more
